There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aravive (ARAV – Research Report) and PainReform (PRFX – Research Report) with bullish sentiments.
Aravive (ARAV)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Aravive, with a price target of $12.00. The company’s shares closed last Wednesday at $1.64.
According to TipRanks.com, Pantginis is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Aravive with a $11.75 average price target.
See Insiders’ Hot Stocks on TipRanks >>
PainReform (PRFX)
In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on PainReform, with a price target of $3.00. The company’s shares closed last Wednesday at $0.54, close to its 52-week low of $0.34.
According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
PainReform has an analyst consensus of Hold.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ARAV:
- Aravive Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates
- Aravive receives orphan drug designation for batiraxcept from FDA
- 2 “Strong Buy” Penny Stocks With Multibagger Potential
- Aravive’s batiraxcept granted orphan designation in pancreatic cancer treatment
- Aravive to Present Positive Updated Data from Phase 1b Trial of Batiraxcept in Combination with Cabozantinib for Treatment of Clear Cell Renal Cell Carcinoma at the 2023 ASCO Genitourinary (GU) Cancers Symposium
